Nuvalent, Inc. Stock Price, News & Analysis

Nuvalent, Inc. (NUVL) reported promising preliminary Phase 1 data for NVL-520 in ROS1-positive NSCLC at the EORTC-NCI-AACR Symposium, supporting its best-in-class potential. The company is progressing in the ALKOVE-1 trial for NVL-655 targeting ALK-positive NSCLC, while NVL-330 shows selectivity for HER2 Exon 20 mutations. A successful upsized public offering raised $264.5 million, extending the cash runway to late 2025. Q3 financials show a net loss of $19.7 million, with R&D expenses at $14.6 million, as the company advances its innovative oncology pipeline.

Nuvalent, Inc. (Nasdaq: NUVL) announced the closing of an upsized underwritten public offering of 7,895,522 shares of Class A common stock at $33.50 per share, generating gross proceeds of approximately $264.5 million. This includes 1,029,850 shares from the full exercise of underwriters' options. The shares were offered under a shelf registration statement effective since August 16, 2022. Notably, J.P. Morgan, Cowen, Piper Sandler, and BMO Capital Markets acted as joint book-running managers for this transaction.

Nuvalent, Inc. (Nasdaq: NUVL) has priced its underwritten public offering of 6,865,672 shares of Class A common stock at $33.50 per share, aiming for gross proceeds of approximately $230 million before expenses. The offering is expected to close on November 3, 2022, pending customary conditions. There is also a 30-day option for underwriters to buy an additional 1,029,850 shares. This offering is part of a shelf registration statement effective since August 16, 2022.

Nuvalent, Inc. (Nasdaq: NUVL) has launched an underwritten public offering of $200 million of Class A common stock, all offered by the company. A 30-day underwriters' option for an additional 15% of shares is also expected. The offering is subject to market conditions, and completion is uncertain. The offering is conducted under a shelf registration statement effective since August 16, 2022. Nuvalent specializes in targeted cancer therapies, focusing on kinase targets. J.P. Morgan and others are managing the offering.

Nuvalent reported preliminary Phase 1 data for NVL-520, a novel ROS1-selective inhibitor, at the EORTC-NCI-AACR Symposium. The treatment showed a favorable safety profile, with no dose-limiting toxicities or serious adverse events observed among 35 enrolled patients. Encouraging signs of efficacy were noted, with 48% of heavily pre-treated ROS1-positive NSCLC patients achieving partial responses. Notable response rates were 78% in patients with G2032R mutations and 73% in those with CNS metastases. NVL-520 aims to address challenges associated with existing treatments, including resistance mutations and CNS adverse effects.

Nuvalent, Inc. (Nasdaq: NUVL) announced new preclinical data for its selective kinase inhibitors NVL-330 and NVL-655 at the 34th EORTC-NCI-AACR symposium. NVL-330 targets HER2 exon 20 insertion mutations and demonstrates selectivity over wild-type EGFR, along with potential for treating brain metastases. Preclinical results indicate NVL-655's activity in ALK-positive tumors, overcoming resistance mutations. Nuvalent continues to advance its pipeline, showcasing significant therapeutic potential against hard-to-treat cancers.

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company, will host a live webcast and conference call on October 28, 2022, at 8:30 a.m. EDT, to discuss preliminary Phase 1 data from the ARROS-1 clinical trial of NVL-520, alongside additional preclinical updates. This event coincides with the 34th EORTC-NCI-AACR Symposium in Barcelona, Spain. Interested parties can access the webcast via Nuvalent’s investor page or by phone using the provided dial-in details.

On October 6, 2022, Nuvalent, Inc. (Nasdaq: NUVL) appointed Dr. Michael L. Meyers, an experienced oncologist and drug developer, to its Board of Directors. Dr. Meyers has been a Senior Clinical Advisor to Nuvalent since 2020 and brings a wealth of experience from his roles at Syndax Pharmaceuticals and Johnson & Johnson. His expertise is expected to enhance Nuvalent's capabilities as it advances its clinical programs, including NVL-520 and NVL-655, which target advanced ROS1-positive and ALK-positive non-small cell lung cancer. The company continues to position itself as a leader in oncology therapies.

Nuvalent, Inc. (Nasdaq: NUVL) announced it will present preliminary results from the ARROS-1 Phase 1/2 trial of NVL-520, aimed at treating advanced ROS1-positive non-small cell lung cancer (NSCLC), during the EORTC-NCI-AACR Symposium from October 26-28, 2022. Additional presentations will feature new preclinical data on NVL-655, an ALK-selective inhibitor, and the selection of NVL-330, targeting HER2 exon 20 insertion-positive tumors. The conference call is scheduled for October 28, 2022, to discuss these developments further.